Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Paul Winer, M.D.

Co-Author

This page shows the publications co-authored by Eric Winer and Rachel Freedman.
Connection Strength

5.995
  1. Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2021 04 06; 113(4):355-359.
    View in: PubMed
    Score: 0.930
  2. Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncol. 2017 Mar 01; 3(3):402-409.
    View in: PubMed
    Score: 0.700
  3. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast. 2010 Apr; 19(2):69-75.
    View in: PubMed
    Score: 0.427
  4. Reducing disparities in breast cancer care: a daunting but essential responsibility. J Natl Cancer Inst. 2008 Dec 03; 100(23):1661-3.
    View in: PubMed
    Score: 0.395
  5. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncol. 2021 04 01; 7(4):609-615.
    View in: PubMed
    Score: 0.232
  6. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
    View in: PubMed
    Score: 0.208
  7. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
    View in: PubMed
    Score: 0.201
  8. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. 2018 05 15; 124(10):2184-2191.
    View in: PubMed
    Score: 0.188
  9. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist. 2017 04; 22(4):386-393.
    View in: PubMed
    Score: 0.175
  10. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol. 2017 Feb; 35(4):421-431.
    View in: PubMed
    Score: 0.173
  11. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373.
    View in: PubMed
    Score: 0.172
  12. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
    View in: PubMed
    Score: 0.168
  13. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
    View in: PubMed
    Score: 0.162
  14. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707.
    View in: PubMed
    Score: 0.155
  15. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501.
    View in: PubMed
    Score: 0.144
  16. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014 Mar 20; 32(9):927-34.
    View in: PubMed
    Score: 0.142
  17. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
    View in: PubMed
    Score: 0.139
  18. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat. 2013 Jun; 139(2):607-16.
    View in: PubMed
    Score: 0.135
  19. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013 Oct; 48(5):1669-83.
    View in: PubMed
    Score: 0.134
  20. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec; 11(6):376-83.
    View in: PubMed
    Score: 0.118
  21. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011 Jan 01; 117(1):180-9.
    View in: PubMed
    Score: 0.112
  22. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):713-9.
    View in: PubMed
    Score: 0.099
  23. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 Apr 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.062
  24. Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
    View in: PubMed
    Score: 0.059
  25. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
    View in: PubMed
    Score: 0.058
  26. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
    View in: PubMed
    Score: 0.058
  27. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021 05; 87(5):673-679.
    View in: PubMed
    Score: 0.058
  28. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131.
    View in: PubMed
    Score: 0.057
  29. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
    View in: PubMed
    Score: 0.056
  30. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.053
  31. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clin Cancer Res. 2019 Sep 01; 25(17):5398-5406.
    View in: PubMed
    Score: 0.051
  32. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737.
    View in: PubMed
    Score: 0.046
  33. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695.
    View in: PubMed
    Score: 0.045
  34. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. J Natl Compr Canc Netw. 2017 03; 15(3):316-324.
    View in: PubMed
    Score: 0.044
  35. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.